Related Experiment Video
Updated: Apr 13, 2026
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Prognostic value of rsf-1/hbxap in human solid tumors: a meta-analysis of cohort studies
Jiayuan Wu1, Liren Hu2, Fenping Wu3
1Department of Nutritional, The Affiliated Hospital of Guangdong Medical College Zhanjiang, Guangdong Province, China.
Purpose:
Recent studies have investigated remodeling and spacing factor 1 (Rsf-1) as a molecular marker in various solid tumors. However, whether or not Rsf-1 exerts a negative or positive effect on the survival of patients with solid cancers remains controversial. Therefore, this study aims to determine whether or not Rsf-1 may be a predicative marker of poor prognosis and aggressive tumor progression.
Methods:
We conducted a meta-analysis of 11 cohort studies (n = 1620 patients) to evaluate the relationship between Rsf-1 and clinical outcome. We included studies with data on overall survival (OS), disease-specific survival (DSS), recurrent-free survival (RFS), metastasis-free survival (MFS), and hazard ratios (HRs) with 95% confidence intervals (CIs).
Results:
High Rsf-1 expression was significantly associated with poor survival in solid tumors. Overall, the combined HR for OS was 1.49 (95% CI = 1.21-1.84, P < 0.001), DSS 3.07 (95% CI = 1.67-5.62, P < 0.001), RFS 2.51 (95% CI = 1.12-5.63, P = 0.025), and MFS 2.14 (95% CI = 1.49-3.06, P < 0.001). In addition, Rsf-1 overexpression was significantly associated with tumor stage (OR = 4.13, 95% CI = 2.84-6.00, P < 0.001), primary tumor (OR = 2.09, 95% CI = 1.58-2.75, P < 0.001), nodal status (OR = 1.95, 95% CI = 1.40-2.72, P < 0.001), and histological grade (OR = 3.09, 95% CI = 2.10-4.54, P < 0.001).
Conclusions:
Rsf-1 may be a predicative marker of poor prognosis and aggressive tumor progression.
